UNIVERSAL SAFETY PRODUCTS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that UNIVERSAL SAFETY PRODUCTS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $23.56M | Jul 29, 2025 |
| FY2025 | Mar 31, 2024 | $19.52M | Jul 29, 2025 |
| FY2024 | Mar 31, 2023 | $22.18M | Jul 12, 2024 |
| FY2023 | Mar 31, 2022 | $19.55M | Jul 14, 2023 |
| FY2021 | Mar 31, 2021 | $3.00M | Jul 22, 2021 |
| FY2021 | Dec 31, 2020 | $5.12M | Jul 22, 2021 |
| FY2021 | Sep 30, 2020 | $6.46M | Jul 22, 2021 |
| FY2021 | Jun 30, 2020 | $2.94M | Jul 22, 2021 |
| FY2021 | Mar 31, 2020 | $3.61M | Jul 22, 2021 |
| FY2021 | Dec 31, 2019 | $3.22M | Jul 22, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $6.83M | Jul 29, 2025 |
| FY2025 | Mar 31, 2024 | $5.60M | Jul 29, 2025 |
| FY2024 | Mar 31, 2023 | $6.35M | Jul 12, 2024 |
| FY2023 | Mar 31, 2022 | $6.03M | Jul 14, 2023 |
| FY2021 | Mar 31, 2021 | $938.2K | Jul 22, 2021 |
| FY2021 | Dec 31, 2020 | $1.52M | Jul 22, 2021 |
| FY2021 | Sep 30, 2020 | $2.10M | Jul 22, 2021 |
| FY2021 | Jun 30, 2020 | $1.08M | Jul 22, 2021 |
| FY2021 | Mar 31, 2020 | $653.7K | Jul 22, 2021 |
| FY2021 | Dec 31, 2019 | $770.0K | Jul 22, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $500.7K | Jul 29, 2025 |
| FY2025 | Mar 31, 2024 | ($695.8K) | Jul 29, 2025 |
| FY2024 | Mar 31, 2023 | $720.4K | Jul 12, 2024 |
| FY2023 | Mar 31, 2022 | ($78.2K) | Jul 14, 2023 |
| FY2021 | Mar 31, 2021 | ($456.8K) | Jul 22, 2021 |
| FY2021 | Dec 31, 2020 | $78.3K | Jul 22, 2021 |
| FY2021 | Sep 30, 2020 | $725.8K | Jul 22, 2021 |
| FY2021 | Jun 30, 2020 | ($79.0K) | Jul 22, 2021 |
| FY2021 | Mar 31, 2020 | ($3.49M) | Jul 22, 2021 |
| FY2021 | Dec 31, 2019 | ($1.01M) | Jul 22, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $402.0K | Jul 29, 2025 |
| FY2025 | Mar 31, 2024 | ($564.8K) | Jul 29, 2025 |
| FY2024 | Mar 31, 2023 | $972.6K | Jul 12, 2024 |
| FY2023 | Mar 31, 2022 | $69.7K | Jul 14, 2023 |
| FY2021 | Mar 31, 2021 | $133.8K | Jul 14, 2022 |
| FY2021 | Mar 31, 2020 | ($1.56M) | Jul 22, 2021 |
| FY2019 | Mar 31, 2019 | $186.9K | Aug 11, 2020 |
| FY2019 | Mar 31, 2018 | ($726.2K) | Jul 15, 2019 |
| FY2018 | Mar 31, 2017 | ($978.1K) | Jul 16, 2018 |
| FY2017 | Mar 31, 2016 | ($1.37M) | Jul 14, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Mar 31, 2023 | $402.7K | Jul 14, 2023 |
| FY2023 | Mar 31, 2022 | $438.2K | Jul 14, 2023 |
| FY2021 | Mar 31, 2021 | $471.5K | Jul 14, 2022 |
| FY2021 | Mar 31, 2020 | $691.9K | Jul 22, 2021 |
| FY2019 | Mar 31, 2019 | $502.8K | Aug 11, 2020 |
| FY2019 | Mar 31, 2018 | $653.9K | Jul 15, 2019 |
| FY2018 | Mar 31, 2017 | $682.5K | Jul 16, 2018 |
| FY2017 | Mar 31, 2016 | $665.3K | Jul 14, 2017 |
| FY2016 | Mar 31, 2015 | $776.8K | Sep 28, 2016 |
| FY2015 | Mar 31, 2014 | $592.5K | Aug 25, 2015 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $6.00M | Jul 29, 2025 |
| FY2025 | Mar 31, 2024 | $5.74M | Jul 29, 2025 |
| FY2024 | Mar 31, 2023 | $4.97M | Jul 12, 2024 |
| FY2023 | Mar 31, 2022 | $5.52M | Jul 14, 2023 |
| FY2021 | Mar 31, 2021 | $5.03M | Jul 14, 2022 |
| FY2021 | Mar 31, 2020 | $4.63M | Jul 22, 2021 |
| FY2019 | Mar 31, 2019 | $4.86M | Aug 11, 2020 |
| FY2019 | Mar 31, 2018 | $4.62M | Jul 15, 2019 |
| FY2018 | Mar 31, 2017 | $4.44M | Jul 16, 2018 |
| FY2017 | Mar 31, 2016 | $4.48M | Jul 14, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($1.05M) | Jul 29, 2025 |
| FY2025 | Mar 31, 2024 | $604.1K | Jul 29, 2025 |
| FY2024 | Mar 31, 2023 | $1.49M | Jul 12, 2024 |
| FY2023 | Mar 31, 2022 | ($1.86M) | Jul 14, 2023 |
| FY2021 | Mar 31, 2021 | $1.39M | Jul 14, 2022 |
| FY2021 | Mar 31, 2020 | $9.2K | Jul 22, 2021 |
| FY2019 | Mar 31, 2019 | $5.9K | Aug 11, 2020 |
| FY2019 | Mar 31, 2018 | $534.9K | Jul 15, 2019 |
| FY2018 | Mar 31, 2017 | ($2.15M) | Jul 16, 2018 |
| FY2015 | Mar 31, 2015 | ($1.37M) | Aug 25, 2015 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Mar 31, 2015 | $0 | Aug 25, 2015 |
| FY2015 | Mar 31, 2014 | ($33.5K) | Aug 25, 2015 |
| FY2014 | Mar 31, 2013 | $11.9K | Aug 4, 2014 |
| FY2012 | Mar 31, 2012 | $9.8K | Jun 27, 2013 |
| FY2011 | Mar 31, 2011 | $65.3K | Jun 28, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $9.82M | Jul 29, 2025 |
| FY2025 | Mar 31, 2024 | $8.33M | Jul 29, 2025 |
| FY2024 | Mar 31, 2023 | $8.40M | Jul 12, 2024 |
| FY2023 | Mar 31, 2022 | $11.52M | Jul 14, 2023 |
| FY2021 | Mar 31, 2021 | $7.50M | Jul 14, 2022 |
| FY2021 | Mar 31, 2020 | $8.18M | Jul 22, 2021 |
| FY2019 | Mar 31, 2019 | $18.91M | Aug 11, 2020 |
| FY2019 | Mar 31, 2018 | $18.90M | Jul 15, 2019 |
| FY2018 | Mar 31, 2017 | $18.39M | Jul 16, 2018 |
| FY2017 | Mar 31, 2016 | $19.15M | Jul 14, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $5.16M | Jul 29, 2025 |
| FY2025 | Mar 31, 2024 | $4.66M | Jul 29, 2025 |
| FY2025 | Mar 31, 2023 | $5.36M | Jul 29, 2025 |
| FY2024 | Mar 31, 2022 | $4.64M | Jul 12, 2024 |
| FY2023 | Mar 31, 2021 | $4.72M | Jul 14, 2023 |
| FY2021 | Mar 31, 2020 | $4.45M | Jul 14, 2022 |
| FY2021 | Mar 31, 2019 | $10.87M | Jul 22, 2021 |
| FY2019 | Mar 31, 2018 | $12.75M | Aug 11, 2020 |
| FY2019 | Mar 31, 2017 | $14.23M | Jul 15, 2019 |
| FY2018 | Mar 31, 2016 | $17.03M | Jul 16, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($7.75M) | Jul 29, 2025 |
| FY2025 | Mar 31, 2024 | ($8.25M) | Jul 29, 2025 |
| FY2024 | Mar 31, 2023 | ($7.55M) | Jul 12, 2024 |
| FY2023 | Mar 31, 2022 | ($8.27M) | Jul 14, 2023 |
| FY2021 | Mar 31, 2021 | ($8.19M) | Jul 14, 2022 |
| FY2021 | Mar 31, 2020 | ($8.46M) | Jul 22, 2021 |
| FY2019 | Mar 31, 2019 | ($2.65M) | Aug 11, 2020 |
| FY2019 | Mar 31, 2018 | ($1.30M) | Jul 15, 2019 |
| FY2018 | Mar 31, 2017 | $963.4K | Jul 16, 2018 |
| FY2017 | Mar 31, 2016 | $3.02M | Jul 14, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $348.1K | Jul 29, 2025 |
| FY2025 | Mar 31, 2024 | $65.1K | Jul 29, 2025 |
| FY2024 | Mar 31, 2023 | $151.5K | Jul 12, 2024 |
| FY2023 | Mar 31, 2022 | $438.7K | Jul 14, 2023 |
| FY2021 | Mar 31, 2021 | $160.6K | Jul 14, 2022 |
| FY2021 | Mar 31, 2020 | $93.8K | Jul 22, 2021 |
| FY2021 | Mar 31, 2019 | $374.5K | Jul 22, 2021 |
| FY2019 | Mar 31, 2018 | $128.2K | Aug 11, 2020 |
| FY2019 | Mar 31, 2017 | $262.4K | Jul 15, 2019 |
| FY2018 | Mar 31, 2016 | $362.7K | Jul 16, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Mar 31, 2022 | $100.0K | Jul 14, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | Jul 29, 2025 |
| FY2025 | Mar 31, 2024 | 0 | Jul 29, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Jul 12, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Jul 14, 2023 |
| FY2021 | Mar 31, 2021 | 0 | Jul 14, 2022 |
| FY2015 | Mar 31, 2015 | 0 | Aug 25, 2015 |
| FY2015 | Dec 31, 2014 | 0 | Aug 25, 2015 |
| FY2015 | Sep 30, 2014 | 0 | Aug 25, 2015 |
| FY2015 | Jun 30, 2014 | 0 | Aug 25, 2015 |
| FY2015 | Mar 31, 2014 | 0 | Aug 25, 2015 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | Jul 29, 2025 |
| FY2025 | Mar 31, 2024 | 0 | Jul 29, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Jul 12, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Jul 14, 2023 |
| FY2021 | Mar 31, 2021 | 0 | Jul 14, 2022 |
| FY2015 | Mar 31, 2015 | 0 | Aug 25, 2015 |
| FY2015 | Dec 31, 2014 | 0 | Aug 25, 2015 |
| FY2015 | Sep 30, 2014 | 0 | Aug 25, 2015 |
| FY2015 | Jun 30, 2014 | 0 | Aug 25, 2015 |
| FY2015 | Mar 31, 2014 | 0 | Aug 25, 2015 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 2.31M | Jul 29, 2025 |
| FY2025 | Mar 31, 2024 | 2.31M | Jul 29, 2025 |
| FY2024 | Mar 31, 2023 | 2.31M | Jul 12, 2024 |
| FY2023 | Mar 31, 2022 | 2.31M | Jul 14, 2023 |
| FY2021 | Mar 31, 2021 | 2.31M | Jul 14, 2022 |
| FY2021 | Mar 31, 2020 | 2.31M | Jul 22, 2021 |
| FY2019 | Mar 31, 2019 | 2.31M | Aug 11, 2020 |
| FY2019 | Mar 31, 2018 | 2.31M | Jul 15, 2019 |
| FY2018 | Mar 31, 2017 | 2.31M | Jul 16, 2018 |
| FY2017 | Mar 31, 2016 | 2.31M | Jul 14, 2017 |